The ECH1 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population targeting the ECH1 gene in the A2780 human ovarian carcinoma cell line. This genetically heterogeneous loss-of-function model enables functional studies without clonal selection, and is suitable for investigating mitochondrial fatty acid beta-oxidation in ovarian cancer metabolism.
The A2780 cell line is an established human ovarian carcinoma epithelial model derived from an untreated patient. Widely used in cancer research, it serves as a platform for drug sensitivity assays, proliferation studies, and metabolic vulnerability analysis. The ECH1 knockout in this background enables dissection of fatty acid oxidation contributions to ovarian cancer cell survival.
ECH1 encodes enoyl-CoA hydratase 1, catalyzing isomerization of 3-trans,5-cis-dienoyl-CoA to 2-trans,4-trans-dienoyl-CoA in mitochondrial beta-oxidation of unsaturated fatty acids. It acts downstream of transcriptional regulators PPARA, PPARD, PPARGC1A, and NR1H4, and interacts with ECHS1 and HADHA within the mitochondrial trifunctional protein complex, contributing acetyl-CoA for the TCA cycle and oxidative phosphorylation. In the fatty acid oxidation pathway, ECH1 functions between ACOX1 and HADHA, with CPT1A controlling the rate-limiting step of fatty acid entry into mitochondria. Knockout of ECH1 disrupts this cascade, impairing unsaturated fatty acid degradation.
In the context of A2780 ovarian cancer cells, ECH1 ablation is predicted to attenuate unsaturated fatty acid catabolism, potentially leading to lipid accumulation and a compensatory shift toward glycolytic metabolism. This metabolic reprogramming may influence cellular energy homeostasis, redox balance, and the synthesis of lipid-derived signaling molecules. Given that many cancers exhibit altered lipid metabolism, this knockout model provides a tool to study how impaired fatty acid oxidation affects ovarian cancer cell proliferation, stress response, and drug susceptibility. The polyclonal nature ensures a range of editing outcomes, mirroring the heterogeneity of tumor cell populations.
This polyclonal knockout pool is suited for functional assays including Seahorse XF analysis of mitochondrial respiration and glycolysis, fatty acid oxidation assays, and LC-MS/MS lipidomics. Western blotting and RT-qPCR can confirm ECH1 disruption and assess pathway compensation. Cell viability, apoptosis, and drug sensitivity assays enable evaluation of ECH1??s role in chemotherapeutic response or metabolic inhibitor effects. For further information, contact Ascent Research.
